Global Search | Novartis United States of America

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 463 results

Media Release / Dec 11, 2019

Novartis announces FDA filing acceptance of Xolair® (omalizumab) for treatment of nasal polyps

EAST HANOVER, N.J., Dec. 11, 2019 /PRNewswire/ -- The submission is based on positive results from the Phase III POLYP 1 and POLYP 2 studies of Xolair in adults with chronic rhinosinusitis with…
Media Release / Jan 21, 2008

Video and Photo: Tekturna HCT®, a Single-tablet Combination of Tekturna®* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure

- Tekturna HCT combines first approved direct renin inhibitor with the diuretic hydrochlorothiazide (HCTZ) in a single tablet- Data show combination of Tekturna and HCTZ resulted in significant…
Media Release / Dec 09, 2007

Photo: New Data Show Gleevec® Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment

- Risk of disease progression continues to drop from the second year of treatment; no patients taking Gleevec in sixth year progressed from initial disease phase- Long-term survival trend may suggest…
Media Release / Jul 10, 2023

US FDA approves expanded indication for Novartis Leqvio® (inclisiran) to include treatment of adults with high LDL-C and who are at increased risk of heart disease

Expanded indication now enables broader use of Leqvio for LDL-C reduction in patients with primary hyperlipidemia (high LDL-C) 1 Leqvio can now be used earlier in LDL-C treatment as an adjunct to…
Media Release / May 17, 2018

Novartis and Amgen announce FDA approval of Aimovig™ (erenumab-aooe), a novel treatment developed specifically for migraine prevention
Media Release / Apr 30, 2018

New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval
Media Release / Jan 03, 2018

Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
Media Release / Dec 06, 2017

Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to premenopausal women with HR+/HER2- advanced breast cancer
Media Release / May 08, 2017

Novartis receives FDA approval for first-of-its-kind Kisqali® Femara® Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer
Media Release / Apr 18, 2017

Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL